Company intelligence / Profile preview

Haisco Pharmaceutical Group Co., Ltd.

Ownership: Public · 002653
Employees: ~5448
Development stage: Commercial

Overview

Haisco has multiple approved drugs in China including Crisugabalin (approved May 2024), a DPP-4 inhibitor (approved June 2024), and Ciprofol Injection (approved 2021). The company has several drugs in clinical trials, with three innovative drugs having submitted NDA.

Therapeutic areas: NephrologyPulmonologyImmunologyOtherGastroenterologyNeurology
Modalities: Small molecule drugsChemical drugsProteolysis-targeting chimeras (PROTAC)Recombinant polypeptideRadionuclide Drug Conjugates (RDC)
Industry: Biotech

Drug pipeline

47 assets

tenofovir alafenamide tartrate

Approved

46 more assets in the full pipeline.

Partnerships

Chiesi Farmaceutici S.p.A (for HSK31858 development)

Financials

Market cap: $10.1B
Total revenue: $651.6M
Enterprise value: $10B

Beyond the preview

Go deeper on Haisco Pharmaceutical Group Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haisco Pharmaceutical Group Co., Ltd..